Lilian Yengi, PhD

Lilian Yengi, PhD, Vice President, Preclinical Development and Biomarkers

Lilian joined Catamaran as Vice President, Preclinical Development and Biomarkers, in April 2022. Prior to Catamaran, Lilian was Senior Director, Preclinical Safety and Translational Biomarkers at Dyne Therapeutics, where she led the development of biomarker and bioanalytical strategies to support the development of therapies for patients with severe muscle diseases. Before her time at Dyne, Lilian was Director of Translational Sciences at bluebird bio where she formulated strategies for post-treatment monitoring of patients treated with CAR-T cell therapy and stem cell-based gene therapy products, overseeing analysis of PK & PD samples from clinical trials across the entire portfolio. Prior to bluebird bio, she was Associate Director at AstraZeneca in the department of drug metabolism and pharmacokinetics, where she led a multidisciplinary team conducting in vitro metabolism, biotransformation, and drug interaction studies supporting multiple therapeutic areas. Lilian started her pharmaceutical career in the department of Drug Safety and Metabolism at Wyeth Pharmaceuticals. Lilian conducted her postdoctoral training at the University of Dundee in Scotland. She holds a PhD in Molecular Genetics from Staffordshire University (UK), an MS in Clinical Biochemistry from Leeds University (UK) and a BS in Biochemistry and Biology from Keele University (UK).